Strategies for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery by Estella M. Davis et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Strategies for the Prevention of Postoperative 
Atrial Fibrillation in Cardiac Surgery 
Estella M. Davis1, Kathleen A. Packard1, Jon T. Knezevich1, 
 Thomas M. Baker2 and Thomas J. Langdon2  
1Creighton University School of Pharmacy and Health Professions 
2Alegent Health, Cardiovascular and Thoracic Surgery 
USA 
1. Introduction 
Atrial fibrillation (AF) occurs in 15% to 50% of patients after cardiac surgery (Bradley et al., 
2005; Dunning et al., 2006). Postoperative atrial fibrillation (POAF) most often develops 
between the second and fifth postoperative day, with a peak incidence in the first two to 
three days. While POAF can be self-limiting, it may also be associated with hemodynamic 
compromise, postoperative stroke, perioperative myocardial infarction (MI), ventricular 
arrhythmias, and heart failure (Echahidi et al., 2008; Kaireviciute et al., 2009). The 
development of POAF is associated with, on average, an additional hospital length of stay 
(LOS) of 1 to 1.5 days (Kim et al., 2001; Zimmer et al., 2003). Some studies, however, report 
that POAF increases hospital LOS by almost 5 days (Aranski et al., 1996; Gillespie et al., 
2006). POAF is also associated with higher hospital costs with an average increase of 
$10,000-$12,600 per hospitalization (Gillespie et al., 2006; Aranski et al., 1996).  
Practice guidelines for the prevention of POAF in patients undergoing cardiac surgery exist 
which include the American College of Chest Physicians (ACCP) 2005 POAF Guidelines, the 
ACCP 2005 Recommendations for the Role of Cardiac Pacing for POAF, the American College 
of Cardiology (ACC)/American Heart Association (AHA)/European Society of Cardiology 
(ESC) 2006 Atrial Fibrillation Guidelines, the ACC/AHA 2004 Coronary Artery Bypass Graft 
Surgery (CABG) Guidelines, the Canadian Cardiovascular Society (CCS) Consensus 
Conference Statements on AF, and the European Association for Cardio-Thoracic Surgery 
(EACTS) 2006 POAF Guidelines and updated ESC/EACTS 2010 AF Guidelines (Bradley et al., 
2005; Maisel & Epstein 2005; Dunning et al., 2006; Fuster et al., 2006; Eagle et al., 2004; Mitchell 
et al., 2005; Kerr & Roy, 2004; European Society of Cardiology ([ESC], 2010) (Table 1). 
The guidelines are consistent in that they all strongly recommend using beta-blockers to 
reduce POAF incidence (ACCP 2005 POAF Guidelines Strength A, ACC/AHA/ESC 2006 AF 
Guidelines and ACC/AHA 2004 CABG Guidelines Class I, Canadian Cardiovascular Society 
AF/POAF Consensus Class I, and ESC 2010 AF Guidelines Class I). The Surgical Care 
Improvement Project (SCIP) National Quality Measures also state that all patients undergoing 
cardiac surgery should receive a beta-blocker during the perioperative period if they were on a 
beta-blocker prior to arrival (Surgical Care Improvement Project [SCIP] Version 3.0a,  
2009). Most institutions have incorporated this requirement into their prospective  
preoperative order sets for all patients without contraindications to beta-blockers. 
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ACCP= American College of Chest Physicians, ACC= American College of Cardiology, AHA= American 
Heart Association, ESC= European Society of Cardiology AF = atrial fibrillation, BB = beta-blocker, CABG = 
coronary artery bypass graft, CV = cardiovascular, EACTS = European Association for Cardiothoracic 
Surgery, POAF= postoperative atrial fibrillation, pts = patients 
Table 1. International Guideline Recommendations for Therapies for the Prevention of 
POAF in Patients Undergoing Cardiac Surgery 
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Though there are no studies examining POAF prophylaxis for patients intolerant of beta-
blockers, effective alternatives include sotalol and amiodarone, depending upon the 
contraindication. The guidelines further specify that amiodarone may be given as an 
alternative or considered in patients at high risk for POAF (Fuster et al., 2006; Eagle et al., 
2004; ESC, 2010; Mitchell et al., 2005a; Kerr & Roy, 2004). Only the previous 2006 EACTS and 
Canadian guidelines support the use of magnesium and state that it may be given in 
addition to other strategies to reduce POAF(Dunning et al., 2006; Mitchell et al., 2005a; Kerr 
& Roy, 2004). Additionally, the most recent ESC guidelines include consideration of 
corticosteroids for the prevention of POAF (ESC, 2010). 
The practice guidelines also recommend utilization of non-pharmacologic strategies for the 
prevention of POAF in cardiac surgery patients (Table 1). The most common strategy 
referred to in the guidelines is cardiac pacing. The most recent 2010 ESC AF guidelines and 
ACCP statement from 2005 recommend that biatrial pacing should be considered for 
prophylaxis (ESC, 2010, Maisel & Epstein, 2005). The CCS statement also recommends that 
atrial pacing with or without a ventricular lead should be considered in patients with 
symptomatic bradycardia (Class 2A recommendation based on Level A evidence) and that 
atrial pacing should be considered if a patient is not on a beta-blocker before surgery (Class 
2A recommendation based on Level B evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). 
Lastly, the CVS guidelines strongly recommend placing temporary ventricular epicardial 
pacing electrode wires at the time of surgery to allow for backup pacing as necessary (Class 
1 recommendation based on Level C evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). 
Other non-pharmacologic strategies mentioned in the guidelines include the use of off-
pump CABG, posterior pericardiotomy, and introperative maze ablation (Mitchell et al., 
2005a; Kerr & Roy, 2004; ESC, 2010). 
2. Pathogenesis of POAF 
The underlying mechanisms for the development of POAF after cardiac surgery are not 
precisely known, but are thought to be multifactorial (Figure 1) (Banach et al., 2010). It has 
been proposed that certain causative mechanisms alter atrial refractoriness and slow atrial 
conduction which results in multiple reentry wavelets circulating within the atria (Baker & 
White, 2007a). Some of these mechanisms include pericardial inflammation, excessive 
production of catecholamines, and volume and pressure changes. Numerous predisposing 
factors such as advanced age, hypertension, diabetes, left atrial enlargement, left ventricular 
hypertrophy, intraoperative and postoperative factors such as atrial injury or ischemia, are 
all thought to impact the development of POAF. Once these conditions exist, a triggering 
event such as premature atrial contraction, electrolyte imbalance, and/or enhanced 
adrenergic or vagal stimulation initiates POAF. Neurohormonal activation is more widely 
recognized as a cause of POAF based on studies linking elevated norepinephrine and 
epinephrine concentrations to the development of POAF (Baker & White, 2007a; Kalman et 
al., 1995). Hence, the majority of interventions that reduce the incidence of POAF modulate 
sympathetic and parasympathetic systems or alter cardiac conduction (Table 1). 
While the mechanisms involved in the development of POAF are multifactorial, there is 
increasing evidence that inflammation also plays a role. Such inflammation may be induced 
by extracorporeal circulation or cardiopulmonary bypass (CPB) with subsequent elevations of 
C-reactive protein (CRP), interleukin-6 (IL-6), and the complement system (Echahidi et al., 
2008; Gaudino et al., 2003; Bruins et al., 1997; Canbaz et al., 2008). Angiotensin II has been 
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HR= heart rate, SD= standard deviation, NADPH= nicotinomide adenine dinucleotide phosphate, 
CABG= coronary artery bypass grafting, ECM= extracellular matrix, CRP= C-reactive protein, IL-6= 
interleukin-6, HSP= heat shock protein, PAI= plasminogen activator inhibitor 
Fig. 1. Pathogenesis of postoperative atrial fibrillation (Banach et al., 2010) 
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shown to increase the production of proinflammatory cytokines, adhesion molecules, and 
selectins (Erlich et al., 2006; Boos et al., 2006). White blood cell count may also be a predictor of 
POAF (Lamm et al., 2006). The degree of inflammation postoperatively can negatively affect 
atrial conduction and duration of atrial fibrillation (Ishii et al., 2005; Tselentakis et al., 2006).  
Oxidative stress has also been implicated in the pathogenesis of atrial fibrillation as the atrial 
tissue undergoes oxidative challenge during CPB (Rodrigo et al., 2008). Patients with POAF 
have been shown to have increased acute myocardial oxidation when compared to patients 
that did not experience POAF (Ramlawi et al., 2007). Specifically, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, an enzyme associated with the formation of the 
reactive oxygen species, superoxide, was found to be independently associated with increased 
risk of POAF (Kim et al., 2008). This may be due to damage of cardiac myocytes through lipid 
peroxidation, breakdown of cell membrane, decreased mitochondrial function, calcium 
overload, and apoptosis (Elahi et al., 2008). Because NADPH is activated by numerous 
mediators including tumor necrosis factor- α (TNF-α) (Griendling et al., 2000), it has been 
proposed as a link between inflammation and oxidative stress in POAF.  
Based on these newly identified pathways, emerging pharmacologic therapies for the 
prevention of POAF have been under investigation including HMG Co-A reductase inhibitors 
(statins), renin-angiotensin-aldosterone-system modulators (including angiotensin converting 
enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)), corticosteroids, omega-
3 fatty acids, ascorbic acid, N-acetylcysteine, and sodium nitroprusside.  
The guidelines suggest additive therapies can be considered for patients at high risk of 
developing POAF. Risk factors that have been identified to increase the risk of POAF 
include advanced age, history of atrial fibrillation, COPD, valvular surgery, hypertension, 
poor left ventricular function, chronic renal insufficiency, diabetes mellitus, rheumatic heart 
disease, withdrawal of preoperative beta-blockers or ACEIs, and increased aortic cross-
clamp and CPB time (Mathew et al., 2004; Baker et al., 2007b; Nisanoglu et al., 2007). No 
simple criteria exist that allow patients to be classified as high risk for the development of 
POAF. A risk index model (Multicenter Study of Perioperative Ischemia Atrial Fibrillation 
Risk Index) (Table 2) was developed to identify subjects at high risk for POAF (Mathew et 
al., 2004). Patients receiving a risk score less than 14 were considered low risk, 14-31 were 
considered medium risk, and greater than 31 were considered high risk for developing 
POAF. Comparison of the predictive ability of the model revealed that the incidence of atrial 
fibrillation was similar in the derivation and validation cohorts across the three risk groups, 
and the area under the receiver operating characteristic curve applied to the final model was 
0.77 (where >0.75 represents a model with good discriminate power). This risk scoring tool 
has been used to stratify patients into risk groups that may benefit from add-on prophylactic 
therapy (Barnes et al., 2006). 
3. Pharmacologic therapies for the prevention of POAF in cardiac surgery 
3.1 Established pharmacologic therapies 
3.1.1 Beta-blockers 
Beta-blockers work at the myocardium antagonizing the effects of catecholamines and have 
been studied extensively for the prevention of POAF. Meta-analyses have shown significant 
reduction in POAF incidence with the use of beta-blocker therapy, resulting in 
recommendation for their use as first-line therapy (Bradley et al., 2005; Dunning et al.; 2006, 
Fuster et al., 2006; Eagle et al., 2004, Kerr & Roy, 2004; [ESC], 2010). The largest meta- 
www.intechopen.com
 
Strategies for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery 211 
Predictor of POAF after CABG 
Risk Score Point 
Assignment 
Age (Y)  
      <30 6 
      30-39 12 
      40-49 18 
      50-59 24 
      60-69 30 
      70-79 36 
      ≥80 42 
History of AF 7 
History of COPD 4 
Concurrent valve surgery 6 
Withdrawal of postoperative treatment  
      ΒB 6 
      ACEI 5 
BB treatment  
      Preoperative and postoperative -7 
      Postoperative -11 
Preoperative and postoperative ACEI treatment -5 
Postoperative treatment  
      Potassium supplementation -5 
      NSAIDs -7 
 = aTotal Points 
aRisk Groups based on summative total point assignment using predictors from table:  
Low risk = Score < 14, Medium risk = Score 14-31, High risk = Score >31 
ACEI = angiotensin converting enzyme inhibitor, AF = atrial fibrillation, BB = beta-blocker, CABG = 
coronary artery bypass graft, COPD = chronic obstructive pulmonary disease, NSAIDs = non-steroidal 
anti-inflammatory drugs, POAF = postoperative atrial fibrillation   
Table 2. Multicenter Study of Perioperative Ischemia Atrial Fibrillation Risk Index (Mathew 
et al., 2004)   
analysis was published in 2002 by Crystal et al. that included 27 randomized controlled 
trials with 3,840 patients (Crystal et al., 2002). Use of beta-blocker therapy decreased the 
incidence of POAF from 33% in the control group compared to 19% in the group receiving 
beta-blockade. This corresponded to a number needed to treat (NNT) of seven patients. A 
large retrospective analysis of the Society of Thoracic Surgeons (STS) database containing 
629,877 patients, demonstrated a reduction in mortality rate with use of peri-operative beta-
blockers (Ferguson et al., 2002). It has been shown that patients receiving perioperative beta-
blockers have reduced mortality compared to control (3.4% versus 2.8%, OR 0.8, 95% CI 0.78 
– 0.82; p<0.001). Efficacy of beta-blockade in the prevention of POAF has been theorized to 
decrease hospital LOS. However, two beta-blocker trials reporting effect on LOS 
demonstrated a non-significant reduction in LOS (-0.66 days; 95% CI, -2.04-0.72) (Cybulsky 
et al., 2000; Wenke et al., 1999).  
The importance of beta-blockers is also affirmed by the two to five-fold increase in the 
incidence of POAF when beta-blockers are discontinued postoperatively (Kalman et al., 
1995; Jideus et al., 2000; Ali et al., 1997). The increase in POAF is thought to be caused by 
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beta-blocker withdrawal and mediated by an upregulation of beta adrenergic receptors and 
sympathetic stimulation (Kalman et al., 1995). Beta-blocker withdrawal is significantly 
associated with a greater than two-fold risk of developing POAF in cardiac surgery patients 
(Adjusted OR 2.17, 95% CI 1.11-4.25, p=0.04) (Lertsburapa et al., 2008). Thus, timing of beta-
blocker administration appears play an important role and evidence supports the 
continuation of beta-blocker therapy from the preoperative stage through postoperative 
management. The guidelines emphasize the importance of reinitiating beta-blockers 
postoperatively without delay (Bradley et al., 2005).  
In addition, the mode of administration of beta-blocker therapy has been evaluated in the 
prevention of POAF. Intravenous administration of metoprolol has demonstrated 
superiority to oral administration when accessing for the prevention of POAF. This is 
theorized to be a result of diminished gastrointestinal absorption with oral administration 
early after surgery. This phenomenon has been demonstrated by Halonen et al., when a 
significant reduction (p=0.036) of POAF occurrence by 11.3% was noted to occur in patients 
assigned to receive intravenous metoprolol therapy compared to patients assigned oral 
therapy (Halonen et al., 2006).  
Controversy exists around selection of the most effective beta-blocker in reducing POAF. 
Two studies have demonstrated improved efficacy of carvedilol when compared to 
metoprolol (Acikel et al., 2008; Haghjoo et al., 2007). This was confirmed by approximately 
18%-20.4% less episodes of POAF in those patients assigned to receive carvedilol.  
Despite the overwhelming evidence to support beta-blocker therapy in the prevention of 
POAF, contraindications to this therapy exist. Alternative pharmacologic and non-
pharmacologic modalities are warranted for patients who cannot tolerate or have the 
following contraindications to beta-blockers: bradycardia (<45 bpm), heart block, cardiac 
failure, severe peripheral edema, sick-sinus syndrome, bronchospastic disease (non-selective 
beta-blockers), and hypotension (SBP < 100 mmHg) with myocardial infarction.  
3.1.2 Amiodarone 
Amiodarone, a class III antiarrhythmic agent, has shown efficacy in the prevention of POAF. 
Its activity is demonstrated through blockade of alpha and beta-adrenergic receptors as well 
as sodium, calcium and potassium channels. Only beta-blockers have more safety and 
efficacy data to support their effectiveness in the prevention of POAF. Most randomized, 
controlled trials have supported the efficacy of amiodarone over placebo in the prevention 
of POAF by showing reduction of occurrence between 12% to 51% (Auer et al., 2004a; 
Barnes et al., 2006; Daoud et al., 1997;  Guarnieri et al., 1999; Giri et al., 2001; White et al., 
2002; Yazigi et al., 2002; Tokmakoglu et al., 2002; White et al., 2003; Mitchell et al., 2005a; 
Budeus et al., 2006; Zebis et al., 2007). Therefore, amiodarone has been granted a class IIa 
recommendation for POAF prophylaxis, behind beta-blockers, according to the 
ACC/AHA/ESC 2006 AF Guidelines, ACC/AHA 2004 CABG Guidelines, 2004 CCS 
AF/POAF Consensus statement, and ESC 2010 (Fuster et al., 2006; Eagle et al., 2004; Kerr & 
Roy, 2004; ESC, 2010). Additionally, the guidelines support amiodarone as prophylactic 
therapy in patients unable to tolerate beta-blockers or in high-risk patients with or without 
beta-blocker therapy (Bradley et al., 2005).  
Two trials evaluating amiodarone versus placebo have demonstrated clear reduction of 
POAF occurrence (Mitchell et al., 2005b; Daoud et al., 1997). Compared to placebo, 
amiodarone reduced POAF incidence by 13.4%-19%. Effectiveness between amiodarone 
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versus other pharmacological agents has been established. Two meta-analysis have been 
conducted evaluating the efficacy of amiodarone in POAF in which a statistically significant 
decrease in incidence was established (Bagshaw et al., 2006; Haan et al., 2002). Comparisons 
of amiodarone effectiveness have been made with agents such as beta-blockers (propranolol, 
metoprolol, and bisoprolol), sotalol, digoxin, and diltiazem. No clear superiority has been 
established amongst comparative trials. Amiodarone has been given in direct combination 
with metoprolol, magnesium, and atrial septal pacing in Bachmanns’s Bundle (Auer et al., 
2004a; Cagli et al.; 2006, White et al., 2003). All of these studies showed amiodarone in direct 
combination with the previous pharmacologic and non-pharmacologic options to be 
superior than that of placebo, with absolute reductions in the incidence of POAF by 20% to 
24% (Auer et al., 2004a; Cagli et al., 2006; White et al., 2003). Combination therapy with 
amiodarone and beta-blockers has been well validated. A meta-analysis also found that 
amiodarone also significantly reduces the LOS by 0.91 days (95% CI, -1.59- -0.24) (Crystal et 
al., 2002). 
Various dosing regimens using IV and/or oral amiodarone with varying administration 
times have been used in the POAF prevention trials. A meta-analysis evaluating 14 
randomized, controlled trials in 2,864 patients, stratified into low (<3 g), medium (3-5 g), or 
high (>5 g) and timing was divided into preoperative or postoperative administration, 
found that cumulative doses of >3 g may be more effective than lower doses and 
preoperative initiation of amiodarone may be unnecessary (Buckley et al., 2007). 
Amiodarone is effective for the prevention of POAF, however it has a complex side effect 
profile that includes QTc interval prolongation, pulmonary and liver toxicity, thyroid 
abnormalities, and visual disturbances. Patients with any of these pre-existing conditions 
may be placed at more risk with the addition of amiodarone for the prevention of POAF 
and the risk versus benefit must be evaluated for each patient. Side effects of amiodarone 
are typically associated with large cumulative doses and prolonged use. However, dosing 
regimens for prophylaxis tend to be short in duration, use lower cumulative dosing, and 
may use more convenient oral doses with or without a short course of IV amiodarone to 
avoid side effects associated with IV administration. The safety of amiodarone in patients 
undergoing cardiac surgery has been evaluated in a meta-analysis reviewing 18 
randomized controlled trials (Patel et al., 2006). Results showed that amiodarone use was 
significantly associated with increased risk of hypotension (OR 1.79; 95% CI 1.04-3.09) and 
bradycardia (OR 2.33; 95% CI 1.41-3.61), especially when the intravenous formulation was 
utilized in high doses (greater than 1 gram). Therefore, clinicians should be cautious using 
amiodarone, especially in combination therapy with beta-blockers or other therapies that 
may cause bradycardia or hypotension. Finally, if amiodarone therapy is added to a 
patient’s medication profile, physical and laboratory exams should be conducted and 
evaluated for the presence of drug-drug interactions or medication side effects.  
3.1.3 Sotalol 
Sotalol, a class III antiarrhythmic that possess beta-blocking activity, has been shown to be 
an effective pharmacological agent for the prevention of POAF. Within the primary 
literature, sotalol has demonstrated absolute reductions in the incidence of POAF between 
13% - 16% (Auer et al., 2004a; Janssen et al., 1986; Suttorp et al., 1991; Weber et al., 1998; 
Evrard et al., 2000). Despite its demonstrated effectiveness, sotalol is contraindicated in 
patients with severe renal insufficiency and should be avoided in patients with heart failure. 
Furthermore, because of its propensity to cause torsades de pointes, it should be avoided in 
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patients with congenital long QT syndrome or a baseline corrected QT interval greater than 
440 msec. Due to its beta-blocking properties, sotalol is contraindicated in patients intolerant 
of beta-blockers. Because of the aforementioned limitations of this agent, sotalol has been 
granted a class IIb recommendation for POAF prophylaxis behind beta-blockers according 
to the ACC/AHA/ESC 2006 AF Guidelines and the ACC/AHA 2004 CABG Guidelines 
(Fuster et al., 2006; Eagle et al., 2004). The most recent 2010 ESC guidelines have assigned a 
Class IIb recommendation for sotalol due to its proarrhythmic risk (ESC, 2010). However, 
the earlier 2006 EACTS guidelines gave sotalol a stronger grade A recommendation based 
upon its comparative efficacy trials versus beta-blockers (Dunning et al., 2006) similar to 
ACC recommendations. 
Patel and Dunning evaluated seven different randomized trials comparing sotalol to 
conventional beta blockers (Patel et al., 2005). Out of the seven trials evaluated, five studies 
demonstrated a statistically significant reduction in POAF for those patients assigned to 
sotalol compared to conventional beta-blockade. The number of patients needed to be 
treated with sotalol to prevent POAF over that of conventional beta-blocker therapy was 
found to be 10. Conversely, because of the pro-arrythmic properties of sotalol, conventional 
beta-blocker therapy may be a safer option.  
3.1.4 Magnesium 
POAF has been associated with decreased postoperative magnesium levels (Kalman et al., 
1995). In fact, plasma magnesium concentration levels less that 0.9 mmol have been found to 
be an independent predictor of POAF (OR 6.7) when using multivariate logistic regression 
models (Treggiari-Venzi et al., 2000). Multiple large, randomized, controlled trials with 
magnesium have failed to demonstrate superiority to usual care with no magnesium in the 
prevention of POAF. These trials included various delivery forms of magnesium including: 
IV infusion (Treggiari-Venzi et al., 2000; Serafimovski et al., 2008; Caspie et al., 1995; Bert et 
al., 2001; Zangrillo et al., 2005), IV infusion based on serum levels (Wilkes et al., 2002), 
magnesium supplementation in maintenance fluids (Colquhoun et al., 1993) and in 
supplementation through cardioplegia solution (Shakerinia et al., 1996). Surprising lower 
cumulative doses of magnesium supplementation (mean cumulative dose 8.2 g) have shown 
to be more effective in reducing the incidence of POAF (OR 0.36, 95% CI 0.23-0.56), 
compared to higher doses (mean cumulative dose 15 g) (OR 0.99, 95% CI 0.70-1.41) (Henyan 
et al., 2005). Results from the same meta-analysis found that preoperative administration of 
magnesium was more effective at decreasing the incidence of POAF (OR 0.46, 95% CI 0.31-
0.67) compared to intraoperative or postoperative administration. Results from several 
meta-analysis (Woodend et al., 1998; Burgess et al., 2006; Shiga et al., 2004; Miller et al., 2005; 
Alghamdi et al., 2005; Henyan et al., 2005; Shepard et al., 2008) have shown inconsistent 
efficacy with magnesium use. A few studies have demonstrated a significant benefit of 
magnesium when compared to usual care with absolute reductions in the incidence of 
POAF by 16% to 34% (Nurozler et al., 1996; Maslow et al., 2000; Kohno et al., 2005). 
However, at this time there is a lack of statistically significant data to support magnesium 
supplementation as monotherapy compared to that of beta-blocker, amiodarone, or sotalol 
therapy in the treatment of POAF (Bert et al., 2001; Solomon et al., 2000; Cagli et al., 2006). 
Only the CCS consensus statement includes magnesium as a Class IIa recommendation, 
however no other guidelines strongly recommend its use for the prevention POAF (Kerr & 
Roy, 2004). Magnesium therapy may be considered in combination with amiodarone and/or 
B-blocker therapy for those patients deemed at high risk or intolerant to the latter 
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medications. If magnesium is utilized in the prevention of POAF, doses of 2.5-5 g have been 
most commonly utilized (Nurozler et al., 1996; Maslow et al., 2000; Kohno et al., 2005). 
When utilized in combination with B-blockers, clinicians should monitor for hypotension as 
combination therapy has been shown to significantly increase the risk of hypotension 
compared to B-blocker therapy alone (24.4% versus 43.5%, p=0.01) (Solomon et al., 2000). 
Finally, it should be noted that magnesium levels need to be monitored carefully 
throughout cardiac surgery and postoperatively regardless if magnesium is being utilized as 
a pharmacological agent for the prophylaxis of POAF. 
4. Emerging pharmacologic therapies for the prevention of POAF in cardiac 
surgery 
4.1 HMG Co-A reductase inhibitors 
HMG Co-A reductase inhibitors (statins) may possess pleiotropic activity beyond lipid 
lowering effects and may be protective against POAF. They have been shown to reduce 
oxidative stress by inhibiting oxidant enzymes, up-regulate antioxidant enzymes, and 
enhance nitric oxide bioavailability (Paraskevas, 2008). It is also proposed that they possess 
direct antiarrhythmic effects mediated through cell membrane stabilization, down-
regulation of the renin-angiotensin-aldosterone-system (RAAS), and protection of ischemic 
myocardium (Howard & Barnes, 2008). They also have been shown to reduce the expression 
of inflammatory mediators (i.e. interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis 
factor- α (TNF-α), C-reactive protein (CRP), cyclooxygenase 2) and decrease the expression 
of CD11b with consequential decreased adherence to endothelial cells of vein grafts (Chello 
et al., 2006; Patel et al., 2007). Therefore, statins may favorably impact the acute 
inflammatory response and alter atrial refractoriness or sympathetic activation that could 
lead to POAF after cardiac surgical procedures.  
Many trials have evaluated the effect of statins on the incidence of POAF in cardiac surgery 
patients. Prospective, randomized trials found an absolute reduction in the incidence of 
POAF of 14% to 22% with statins compared to placebo or usual care (Chello et al., 2006; Patti 
et al, 2006; Song et al., 2008; Ji et al., 2009). The largest and most robust of these three trials 
was the Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study 
(ARMYDA-3) in which a significant reduction in POAF of 22% and a reduction in LOS of 0.6 
days was observed with a statin compared to placebo (Patti et al., 2006). This study enrolled 
only patients who had no previous history of statin use and these patients could have less 
risk of pre-existing atherosclerotic disease and subsequently been at lower risk for 
developing POAF.  
Other statin trials in CABG patients are observational, cohort studies with conflicting results 
of no benefit (Thielmann et al., 2007; Mithani et al., 2009) or a significant reduction in the 
incidence of POAF (Lertsburapa et al., 2008; Subramaniam et al., Mariscalco et al., Ozaydin 
et al., 2007; Miceli et al., 2009a;  Kinoshita et al., 2010).  
One study evaluated the combination of a statin and beta-blocker on the incidence of POAF. 
Monotherapy with atorvastatin or a beta-blocker reduced the risk of POAF by 61% (OR 0.39; 
95% CI 0.18-0.85) and 82% (OR 0.19; 95% CI 0.08-0.44), respectively. However, the 
combination of atorvastatin plus a beta-blocker performed better by reducing the risk of 
POAF by 90% (OR 0.10; 95% CI 0.02-0.25) (Patti et al., 2006). The combination of 
preoperative and postoperative beta-blocker and amiodarone prophylaxis in 40% of patients 
may have also influenced the positive results in the statin group (Lertsburapa et al., 2008). 
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A few studies have been conducted to determine the optimal prophylactic dose of statins. 
Kourlioros et al found that simvastatin 40 mg and atorvastatin 40 mg had the greatest effect on 
POAF (Kourlioros et al., 2008). Simvastatin 20 mg and atorvastatin 20 mg maintained efficacy 
compared to control, but no difference was found at 10 mg or 80 mg of either drug. 
Lertsburapa et al analyzed patients by converting their statin dose to atorvastatin equivalents. 
Relative statin doses ≥40 mg of atorvastatin resulted in the greatest reduction in POAF by 55% 
(OR 0.45; 95% CI 0.21-0.99) (Lertsburapa et al., 2008). The 20 mg atorvastatin dose still showed 
a significant benefit (OR 0.6; 95% CI 0.23-0.99), while the < 20 mg dose showed no significant 
benefit (OR 0.75; 95% CI  0.47-1.20). Mithani et al found in their multivariate analysis that 
POAF was less common among patients taking higher doses of statins compared to those 
taking simvastatin < 20 mg/day (28% versus 34%, p=0.03). (Mithani et al., 2009)  Comparing 
statins, only one prospective, observational study found that POAF was less frequent in 
patients receiving pravastatin compared to atorvastatin (9.5% versus 34.9%, p=0.0257) or no 
statins (9.5% versus 34.2%, p=0.0025). (Tamura et al., 2010) 
A long-term study found that statins’ benefit may extend beyond the immediate postoperative 
period and in outcomes other than POAF. Statins reduced the composite endpoint of death, 
MI, and unstable angina at both 60 days (OR 0.09; 95% CI 0.01-0.70, p=0.02) and one year post-
CABG (OR 0.26; 95% CI 0.015-0.4, p<0.0001) (Dotani et al., 2000). Kaplan-Meier 30 day atrial 
fibrillation-free survival curves also indicated benefit with statins (Patti et al., 2006; Mariscalco 
et al., 2007; Ozaydin et al., 2007; Song et al., 2008). One meta-analysis confirmed the protective 
benefit of preoperative statins for POAF and early all cause mortality. This study also found a 
significant reduction in the risk of stroke by 26% with statins when compared to controls (OR 
0.74; 95% CI 0.60-0.91) (Laikopoulos et al., 2008, Chen et al., 2010). While statins appear to 
reduce POAF in the short term setting in cardiac surgery patients, a recent meta-analysis 
found that longer term (≥ 6 months of follow-up) use of statins in cardiac patients was not 
associated with a significant reduction in AF (OR 0.95; 95% CI 0.88-1.03, p=0.24), however only 
one of the 22 studies was in CABG patients (Rahimi et al., 2011).  
Statins have shown benefit in reducing the risk of POAF, LOS, mortality, and 30 day atrial 
fibrillation-free survival. It is less clear which statin, what dose, and for what duration will 
achieve the greatest benefit. While the combination of statins and standard beta-blocker 
therapy is safe, certain statins, such as simvastatin, should only be used in reduced doses 
with the combination of amiodarone due to risk of myalgias or rhabdomyolysis (FDA Alert 
2008). Larger, prospective, randomized control trials are necessary to confirm that statins are 
effective in reducing the occurrence of POAF in addition to beta-blockers.  
4.2 Renin-angiotensin-aldosterone-system (RAAS) modulators 
An increasing number of investigations are being conducted to evaluate the association 
between the RAAS, the inflammatory process, and atrial fibrillation. Interruption of the 
RAAS by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 
prevents the production of the regulatory hormone angiotensin II, which plays a key role in 
controlling blood pressure, vascular smooth muscle tone, aldosterone release, and sodium 
resorption from the renal tubules (Boos et al., 2006). Beyond these actions, angiotensin II has 
been implicated in increasing the production of pro-inflammatory cytokines (i.e. IL-6, IL-8, 
TNF-α), adhesion molecules, selectins, and the recruitment of neutrophils (Boos et al., 2006). 
Histologic evidence exists that persistent and paroxysmal atrial fibrillation leads to altered 
angiotensin II receptor expression (Erlich et al., 2006; Boos et al., 2006). Genetic 
polymorphisms in the angiotensinogen gene are also two to three times more likely to have 
www.intechopen.com
 
Strategies for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery 217 
non-familial atrial fibrillation (Tsai et al., 2004), further supporting the role RAAS plays in 
the development of atrial fibrillation. ACEIs and ARBs have been shown to reduce the 
incidence of atrial fibrillation in patients with congestive heart failure, hypertension, or post 
MI (Makkar et al., 2009).  
Three potential mechanisms have been suggested to explain the antiarrhythmic benefits of 
ACEIs and ARBs against atrial fibrillation. It is proposed that they improve left ventricular 
hemodynamics, reduce atrial stretch, suppress angiotensin-induced fibrosis, and direct 
modulation of potassium and calcium ion channel function. These ACEI/ARB-induced 
changes decrease atrial vulnerability and may diminish the initiation of atrial fibrillation 
(Erlich et al., 2006).  
Few prospective, controlled studies have been conducted to assess the efficacy of ACEIs or 
ARBs in reducing the incidence of POAF in cardiac surgery patients (White et al., 2007a; 
Ozaydin et al., 2008a). One study randomized patients to an active intervention of ACEI or 
combination of ACEI/ARB and then compared these two treatment groups to a historical 
control. Greater than 85% of patients randomized to ACEI or combination were also on beta-
blockers preoperatively and 97% of patients in the historical control group were on beta-
blockers (Ozaydin et al., 2008a). Despite the high percentage of preoperative beta-blocker 
use in the control group, the combination of an ACEI/ARB or an ACEI alone proved 
superior to usual care with absolute reductions in the incidence of POAF compared to 
controls by 23% and 21%, respectively. There was no difference in the magnitude of the 
reduction of the incidence of POAF using the combination of an ACEI/ARB compared to an 
ACEI alone. The authors also found that both the combination ACEI/ARB or ACEI alone 
significantly reduced the risk of POAF by 72% and 66%, respectively (RR 0.28; 95% CI 0.09-
0.83 and RR 0.34; 95% CI 0.12-0.93, respectively). The other study examined the effect of 
ACEI or ARBs on development of POAF from a nested cohort of patients from the AFIST II 
and III trials (White et al., 2007a). This study also found that preoperative use of ACEIs or 
ARBs were protective in reducing the risk of POAF by 29%, however the magnitude of the 
reduction was not statistically significant (adjusted OR 0.71; 95% CI 0.42-1.20). The clinical 
reduction in risk of POAF in patients on ACEIs or ARBs could have been influenced by 84% 
of the total population of patients receiving postoperative beta-blockade and 38% receiving 
amiodarone for POAF prophylaxis, therefore it remains unclear from that study the 
independent effect ACEIs or ARBs on POAF. Multivariate logistic regression analysis found 
that postoperative beta-blocker (adjusted OR 0.47, 95%CI 0.24-0.89) and prophylactic 
amiodarone (adjusted OR 0.32, 95%CI 0.18-0.57) were both negative predictors of POAF, 
thus decreasing the risk for POAF by 53% and 68%, respectively (White et al., 2007a). 
Cohort studies conducted to evaluate the risk factors associated with the development of 
POAF in cardiac surgery patients found that preoperative and postoperative use of ACEIs 
or ARBs decreased the risk of POAF by 38% (OR 0.62; 95% CI 0.48-0.79; p<0.001) and that 
withdrawal of ACEI or ARB increases the risk of POAF by 1.7 times (OR 1.69; 95% CI 1.38-
2.08; p<0.001) (Mathew et al., 2004)  while another study in cardiac surgery patients with EF 
≤ 50% confirmed this association that both ACEIs decreased the risk of POAF by 73% (OR 
0.27, 95% CI 0.12-0.62, p=0.002) and ARBs by 79% (OR 0.21; 95% CI 0.07-0.62, p=0.005) 
(Ozaydin et al., 2010). Unfortunately, three other cohort studies did not confirm a protective 
effect of ACEIs or ARBs with no significant reduction in the risk of POAF compared to 
controls (Coleman et al., 2007; Miceli et al., 2009b; Rader et al., 2010). The largest of these 
cohort studies, evaluating over 10,000 patients, found that preoperative ACEI doubled the 
risk of death (OR 2.00, 95% CI 1.17-3.42; p= 0.013) and that preoperative ACEIs were an 
independent predictor of mortality (p = 0.04), postoperative renal dysfunction (p=  0.0002), 
use of inotropic drugs (p < 0.0001), and new onset POAF (p < 0.0001). (Miceli et al., 2009b) A 
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significant reduction may not have been observed in these studies as patients were 
propensity score matched for common predictors of atrial fibrillation. Thus groups could 
have been at high risk for the development of POAF (Coleman et al., 2007; Rader et al., 
2010). 
Further prospective, controlled trials are needed evaluate the impact of ACEIs or ARBs on 
the development of POAF. These studies will provide more definitive evidence concerning 
the effectiveness of ACEIs and ARBs in the prevention of POAF following cardiac surgical 
procedures. If ACIEs or ARBs are used in combination with standard therapies for the 
prevention of POAF, they must be used with caution or avoided in patients with renal 
dysfunction or electrolyte abnormalties, specifically hyperkalemia.  
4.3 Corticosteroids 
Corticosteroids have been traditionally utilized in cardiac surgeries to reduce inflammation 
in an effort to achieve early extubation, enhance pulmonary function recovery, or decrease 
postoperative nausea and vomiting. Inflammatory biomarkers increase in patients 
undergoing cardiothoracic surgery and inflammation appears to play a role in the 
development of POAF. 
Studies evaluating corticosteroids have used various types of intravenous (IV) steroids, 
doses, and regimens. Two studies used beta-blockers postoperatively in all of their patients 
found that corticosteroids were superior to placebo with absolute reductions in the 
incidence of POAF of 18% to 30% (Prasongsukarn et al., 2005; Halonen et al., 2007). 
However other trials failed to show a significant benefit (Chaney et al., 1998; Halvorsen et 
al., 2003) in reducing incidence of POAF compared to placebo or usual care. Halonen et al 
further reported that after adjusting for potential unbalanced confounders, that 
hydrocortisone continued to be effective in reducing the risk of POAF by 46% (HR 0.54; 95% 
CI 0.35-0.83) with treatment of only 5.6 patients needed to prevent one occurrence of POAF 
(Halonen et al., 2007). The authors further performed a meta-analysis combining results 
from their trial with two other similar trials for a total of 621 patients (Prasongsukarn et al., 
2005; Halvorsen et al., 2003). They found that corticosteroid therapy significantly reduced 
the risk of POAF by 33% (OR 0.67; 95% CI 0.54-0.84) (Halonen et al., 2007). Two other meta-
analyses confirmed this finding where corticosteroids significantly reduced the risk of POAF 
by 29% (OR 0.71; 95% CI 0.59-0.87) and 45% (OR 0.55; 95% CI 0.39-0.78) and show a 
significant decrease in LOS with steroids of 0.6 days and 1.6 days (Whitlock et al., 2008; 
Baker et al., 2007b). 
At this time, specific dosing of corticosteroids that may confer optimal protection against 
POAF is unkown. Baker et al converted the steroid dosing to dexamethasone equivalence 
based on total cumulative dose and relative potencies and found that reduction in POAF 
appeared greatest in patients receiving intermediate doses of corticosteroids (50-120 mg 
dexamethasone equivalent), while lower (≤ 8 mg dexamethasone equivalent) and higher 
(236-2850 mg dexamethasone equivalent) dosing resulted in blunted effects (Baker et al., 
2007b). The most recent meta-analysis by Ho et al converted steroid dosing to 
hydrocortisone equivalence and found a significant reduction of POAF in patients receiving 
low (< 1,000 mg hydrocortisone equivalent) and intermediate (1,000-10,000 mg 
hydrocortisone equivalent) doses of steroids (Ho & Tan, 2009). 
While corticosteroids can attenuate biomarkers shown to regulate the inflammatory 
response leading to the development of POAF, they are also associated with side effects that 
may inhibit their widespread use. Cardiac surgery patients who have received 
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corticosteroids have been shown to have peak white blood cell counts were higher up to 14 
days postoperatively, higher blood glucose and larger insulin requirements (Sano et al., 
2006), greater risk of wound and infectious complications (Whitlock et al., 2008). Therefore it 
may be necessary to avoid corticosteroids in patients with uncontrolled hyperglycemia, 
infection, or edema. 
Corticosteroids can target the inflammatory process for the prevention of POAF in patients 
undergoing cardiac surgery. While some studies found a reduction in the incidence of POAF 
using corticosteroids as prophylaxis in cardiac surgery patients receiving standard beta-
blocker therapy, there is no consensus on which steroid, dose, and duration has the greatest 
benefit. Only the 2010 European guidelines recommend corticosteroids for prophylaxis of 
POAF in cardiac surgery patients and include suggested dosing in dexamethasone equivalent 
for the prevention of POAF with a Class 2B recommendation, stating however that there is risk 
associated with using them (ESC, 2010). The most relevant risk in hospitalized patients after 
cardiac surgery includes steroid-induced hyperglycemia or leukocytosis. Corticosteroids may 
play a future role in targeting the inflammatory process in patients undergoing cardiothoracic 
surgery, however larger clinical trials are necessary to confirm if corticosteroids are effective in 
reducing the occurrence of POAF in addition to beta-blockers. 
4.4 Omega-3 fatty acids 
The ability of omega-3 fatty acids to reduce the occurrence of POAF is thought to result from 
a stabilizing effect on the myocardium, anti-inflammatory properties, and possibly 
antioxidant activity (Kris-Etherton et al., 2002; Korantzopoulos et al., 2006). Calo et al 
performed a prospective, randomized, open label study in 160 patients assessing the impact 
of N-3 polyunsaturated fatty acids (PUFA) 2 g/day on the incidence of POAF in cardiac 
surgery patients (Calo et al., 2005). Approximately 60% of patients in both groups were on 
preoperative beta-blockers. They found a significant reduction in incidence of POAF (15.2% 
versus 33.3%, respectively, p=0.013) and mean LOS (7.3 + 2.1 days versus 8.2 + 2.6 days, 
respectively, p=0.017) in patients receiving PUFA compared to control patients. Another 
small prospective, randomized study found that administration of IV PUFA at 100 mg fish 
oil/kg/day significantly reduced the incidence of POAF compared to control (17.3% vs. 
30.6%, p<0.05) however this study did not mention the percentage of patients on beta-
blocker therapy (Heidt, et al., 2009). Similar to other new agents showing studies with 
conflicting results for the prevention of POAF in cardiac surgery patients, two small, 
prospective, randomized, double blind, placebo controlled studies found no benefit using 
PUFA ~ 2 g/day therapy (Heidarsdottir et al., 2010;  Saravanan et al., 2010). Further studies 
are warranted to determine if omega-3 fatty acids are viable add-on prophylactic therapy or 
alternative for patients unable to take beta-blockers. 
4.5 Ascorbic acid 
The ability of ascorbic acid (vitamin C) to prevent POAF is thought to occur due its antioxidant 
properties and potential to attenuate inflammation and electrical remodeling (Korantzopoulos 
et al., 2005). Vitamin C has been studied in prospective trials for the prevention of POAF in 
cardiac surgery patients (Carnes et al., 2001; Eslami et al., 2007). Both studies demonstrated 
significant benefit using vitamin C compared to usual care with an absolute reduction in 
POAF between 19-22%, but no reduction in mean LOS. Both studies also had substantial rates 
of both pre- and postoperative beta-blocker utilization. Due to the low cost and relative safety 
of this drug, larger placebo-controlled trials appear to be warranted. 
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4.6 N-Acetylcysteine 
N-acetylcysteine (NAC) has been theorized to prevent POAF based on its antioxidant activity 
as a free radical scavenger and ability to reduce cellular damage in the atrium (Carnes et al., 
2007). Two recent studies, which were randomized and placebo-controlled, found conflicting 
results with NAC in the prophylaxis of POAF (El-Hamamsy et al, 2007; Ozaydin et al., 2008b). 
The first study failed to demonstrate a significant reduction in the incidence of POAF (7% with 
NAC versus 12% with placebo, p=0.7). A more recent study, which included valve surgeries, 
did show a significant benefit with NAC compared to placebo (5% versus 21%, p=0.01). After 
controlling for perioperative beta-blocker use, NAC was still associated with a significant 
reduction in POAF (OR 0.17, 95% CI 0.04-0.69, p=0.01). Neither study found a significant 
reduction in LOS. Both studies reported substantial preoperative beta-blocker use while 
Ozaydin et al also reported substantial postoperative beta-blocker utilization. Two conflicting 
meta-analyses have been recently published, one that found a statistically significant reduction 
in POAF with NAC use (36%, 95% CI 2-58%, total n=1,338) and one larger one that did not (OR 
0.67, 95% CI 0.37-1.22, p=0.19, total n=1,407) (Baker et al., 2009; Wang et al., 2011). Large, 
prospective, randomized clinical trials are necessary to determine if NAC is effective in 
reducing the occurrence of POAF in addition to beta-blockers.  
4.7 Sodium nitroprusside 
One pilot study evaluated sodium nitroprusside as an agent for POAF prophylaxis 
compared to placebo (Cavolli et al., 2008). This study demonstrated a significant reduction 
in the incidence of POAF when compared to placebo (12% versus 36%, p=0.005) and a 
significant reduction in mean LOS (7.3 + 0.7 days versus 9.1 + 1.2 days, p<0.001). The 
authors suggest that nitric oxide (NO) function may be disrupted due to ischemia-
reperfusion injury and that administration of NO donors such as nSNP could recover this 
function. SNP may also reduce POAF by reducing left atrial stretching due to preload and 
afterload reduction. This study also showed a significant reduction in serum CRP levels in 
patients given SNP when compared to placebo (p<0.05), suggesting some possible effects on 
inflammation. Though not significant, more patients randomized to SNP received 
preoperative beta-blockers when compared to the placebo group (68% versus 58% p=0.303). 
Postoperative beta-blocker use was not addressed. Likewise, patients in this study had 
relative preserved ejection fractions (60-61%). Currently, SNP is routinely used in 
institutions for the management of postoperative hypertension. Patients receiving this 
medication may also experience an additional benefit of arrhythmia prevention. 
4.8 Dofetilide 
Dofetilide has been compared to placebo for postoperative atrial tachycardia (POAT) 
prophylaxis in one study (Serafimovski et al., 2008). The investigators found that patients 
receiving dofetilide prophylaxis experienced a significant reduction in the incidence of 
POAT, including atrial fibrillation and atrial flutter, when compared to placebo (18% versus 
36%, p<0.017). There was no significant decrease in mean LOS. Although the use of 
postoperative beta-blockers was not reported, the authors conclude that the dofetilide group 
experienced a significant decrease in POAT independent of concomitant beta-blocker use 
based on multivariate logistic regression accounting for preoperative beta-blocker use. Due 
to cost, stringent prescribing and monitoring guidelines, and lack of robust head to head 
trials, dofetilide is not currently recommended as first line POAF prophylaxis. Like sotalol, 
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it also carries a greater risk of Torsades and should be avoided in patients with prolonged 
QT intervals. It could be considered for add on therapy in high risk patients or in patients 
intolerant of beta-blockers but should first be compared to other traditional class III 
antiarrhythmics such as amiodarone or sotalol in head to head trials. 
4.9 Levosimendan 
Levosimendan is an intravenous calcium sensitizer agent that is used for the treatment of 
acute decompensated heart failure. It increases myocardial contraction without increasing 
myocardial oxygen consumption and produces coronary and peripheral vasodilation 
(Lilleberg et al., 1998). While the drug is not approved and will not be pursued for FDA 
approval in the US, it has been shown in one study to significantly reduce the incidence of 
POAF and increase stroke volume in patients with ejection fraction <30% when compared to 
milrinone (50% for milrinone, 5% for levosimendan started post anesthesia, and 35% for 
levosimendan started after cross clamp release, p<0.01) (De Hert et al., 2008). Very few 
patients in this study, however, were taking preoperative beta-blockers (~13-14%) and all 
patients received dobutamine after the release of the cross clamp. 
5. Unestablished pharmacologic therapies for the prevention of POAF in 
cardiac surgery 
5.1 Propafenone, procainamide, digoxin and calcium channel blockers  
Given the availability of just a few trials with inconsistent results, propafenone is not 
currently recommended as first-line for POAF prophylaxis (Bradley et al., 2005; Dunning et 
al., 2006; Fuster et al., 2006; Eagle et al., 2004). Its use may be limited by its proarrhythmic 
effects in patients with structural heart disease. Current available evidence also does not 
support the use of procainamide for POAF prophylaxis. Although based on limited 
evidence, preoperative “digitalization” was historically used to prevent POAF. Currently, 
digoxin does not have an indication for POAF prophylaxis but can be used for rate control 
once atrial fibrillation occurs (Bradley et al., 2005). Only the non-dihydropyridine calcium 
channel blockers (non-DHP-CCB) diltiazem and verapamil, have evidence supporting their 
effectiveness for POAF prophylaxis from a meta-analysis evaluating twelve small studies 
encompassing 719 patients (Wijeysundera et al., 2003). However, two other meta-analyses 
found a non-significant reduction (Andrews et al., 1991) and even an increase in the risk of 
POAF (Woodend et al., 1998) with the CCBs. Because of this and the risk of atrioventricular 
block and low-output syndrome, especially in combination with beta-blockers, the 
guidelines recommend against routine use of CCBs for POAF prophylaxis and that the non-
DHP-CCBs, diltiazem or verapamil, be reserved for rate control only once POAF has 
occurred (Bradley et al., 2005; Eagle et al., 2004). 
5.2 Thiazolidinediones 
Thiazolidinediones (TZDs) may affect POAF through pleiotropic anti-inflammatory activity 
against macrophage activation and pro-inflammatory cytokines (Consoli & Devangelio, 
2005; Ricote et al., 1998). One study evaluated a nested cohort study of diabetic patients 
from the AFIST I, II, and III trials (Giri et al., 2001; White et al., 2003; White et al., 2007a) 
assessed whether the use of TZDs affected the incidence of POAF in diabetic patients who 
were also receiving beta- blockers and amiodarone (Anglade et al., 2007). In addition to 
substantial pre- and postoperative beta-blocker use, 43.8% of control patients and 35% of 
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TZD patients received amiodarone. Despite this, the study was unable to show a significant 
reduction in POAF. This may have been due to a lack of power due to small sample size, 
dilution of effect from concomitant beta-blocker and/or amiodarone use, or increased fluid 
retention associated with TZD use. In this same analysis, statins did demonstrate a 
significant reduction in POAF (28% versus 37%, p<0.05). This suggests that the most likely 
reason TZDs were of no benefit is due to their risk of fluid accumulation thereby attenuating 
any anti-inflammatory effect (Lertsburapa K, 2008). At this time, TZDs can not be 
recommended as an option for POAF prophylaxis, either alone or in combination with beta-
blockers. 
5.3 Triiodothyronine 
The rationale behind the use of triiodothyronine (T3) for POAF prophylaxis lies in the 
observation that CPB results in a euthyroid sick or low T3 state (Klemperer et al., 1996). The 
mechanism by which T3 may prevent POAF is unknown (Reichert & Verzino, 2001). 
Interestingly, it has been shown that POAF is more common in patients with subclinical 
hypothyroidism when compared to those with normal thyroid function, after adjustments 
for other variables (Park et al., 2009). One demonstrated that intravenous administration of 
T3 starting at the time of cross clamp removal significantly decreases the incidence of POAF 
when compared to placebo (24% versus 46%, p=0.009) (Klemperer et al., 1996). All patients 
had a left ventricular ejection fraction of less than 40%. While T3 administration was 
associated with significantly higher postoperative cardiac indices and lower systemic 
vascular resistance, there was no significant difference in LOS (Klemperer et al., 1995). The 
authors previously reported data from this same study but included those patients with a 
history of preoperative atrial fibrillation (Klemperer et al., 1995). In this earlier study, there 
were no significant differences in the incidence of SVT between the two treatment groups. 
The authors do not report postoperative beta-blocker use but suggest that because the study 
population was more ill (ejection fraction <40%), beta-blockade may not be as effective and 
add-on therapy would be warranted. None of the guidelines currently recommend the use 
of T3 due to low quality of evidence (Bradley et al., 2005). Until more data becomes available 
supporting its for POAF prophylaxis, it should not be routinely utilized.  
6. Non-pharmacologic strategies for the prevention of POAF in cardiac 
surgery 
6.1 Pacing 
The use of right atrial, left atrial, bi-atrial and pacing of the Bachman’s bundle all have been 
evaluated in their merit in reducing post-operative supraventricular arrhythmias. The 
mechanism of atrial fibrillation is in part believed to be related to changes in the substrate on 
a temporary basis which causes lengthening of the P-R interval thereby allowing re-entrant 
POAF (Fan et al., 2003). There is evidence that bi-atrial pacing is beneficial especially in the 
age group over 70 (Gerstenfeld et al., 2001). While bi-atrial pacing has demonstrated some 
success it is noted the right atrial pacing alone is less favorable (Chung et al., 1996). Pacing 
thresholds and stability of the pacing wire has become problematic and alternate sources of 
pacing locations have been sought out (Goette et al., 2002). Bachman’s bundle, a thick 
fibrous strip of muscle at the roof of both atria that crosses the intra-atrial septum has been 
demonstrated to have low pacing thresholds for at least five days post-operatively. This site 
may reduce intra-atrial conduction times thus reducing POAF (Goette et al., 2002). 
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In a meta-analysis of 10 clinical trials it was demonstrated that atrial pacing at the right 
atrium, left atrium or Bachman’s bundle produced a decrease in atrial fibrillation (Fan et al., 
2003). These 10 studies are limited by multiple pacing protocols, including using complex 
algorithms, fixed pacing and flexible algorithms. Eight of these studies demonstrated that 
bi-atrial pacing reduced the odds of POAF by 54% (OR=0.46; 95% CI 0.3-0.71). There was a 
significant lack of use of beta-adrenergic blocking drugs used in the post-operative phase in 
the meta-analysis at 56%. In a small group of patients (n=80) who underwent valvular 
surgery it was found that bi-atrial synchronous pacing for 72 hours decreased atrial 
fibrillation from 45% in the control group to 20% in the paced group (p=0.02) (Debrunner et 
al., 2004). It is noted that only 30% of this small group were exposed to pre-operative beta-
adrenergic blockade, and post-operative use was not collected.  
Pacing of the atria is not without risk. In a randomized trial of 100 patients it was found that 
atrial fibrillation occurred in 27.5% of the paced patients and 28.6% of the control group 
(Chung, 2003). There was an increase in atrial ectopy (10 fold increase) in the group of 
patients whom developed atrial fibrillation (Chung, 2003). It was hypothesized that 
inconsistent pacing in the atria, under sensing and intermittent loss of capture were factors 
in the increase in ectopy (Chung, 2003). A sub-analysis of patients paced at a lower rate (80 
bpm) and use of an algorithm that maintained the atrial rate 50 ms above the intrinsic rate, 
demonstrated no difference in atrial fibrillation rates (Chung, 2003).  
The most recent 2010 European AF guidelines recommend that biatrial pacing should be 
considered for prophylaxis (Class 2B recommendation based on Level A evidence) (ESC, 
2010). Earlier publication in 2006 by EACTS for the guidelines for POAF after cardiothoracic 
surgery in 2006 (Grade A recommendation based on Level 1B studies) and in 2005 by the 
American College of Chest Physicians (ACCP) (Strength: B, Evidence: good, Net Benefit: 
small/weak) both similarly recommend biatrial pacing for prophylaxis (Dunning et al., 
2006; Maisel & Epstein, 2005). (Table 1) Specifically, the 2005 ACCP guideline specifically 
recommends not using unilateral pacing of the right or left atrium. (Strength: I, Evidence: 
fair, Net Benefit: small/weak) (Maisel & Epstein, 2005). Furthermore, the 2006 EACTS 
guidelines recommend that temporary pacing should be used in high risk patients receiving 
beta-blockers and amiodarone for prophylaxis as protection from complications of 
bradycardia (Grade A recommendation based of Level 1B studies). The CCS guideline also 
recommends considering atrial pacing with or without a ventricular lead in patients with 
symptomatic bradycardia (Class 2A recommendation based on Level A evidence) and those 
patients who are not on a beta-blocker before surgery (Class 2A recommendation based on 
Level B evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004). Last, the CCS guidelines 
strongly recommend placing temporary ventricular epicardial pacing electrode wires at the 
time of surgery to allow for backup pacing as necessary (Class 1 recommendation based on 
Level C evidence) (Mitchell et al., 2005a; Kerr & Roy, 2004).  
6.2 Posterior pericardiotomy 
The pathophysiology of posterior pericardiotomy is based upon adequate drainage of the 
pericardial space thereby reducing pericardial effusion (Biancari, 2010). Only the earlier 
European guidelines do include posterior pericardiotomy as a non-pharmacologic option 
for the prevention of POAF (Grade B recommendation based on Level 1B studies) (Dunning 
et al., 2006). A recent meta-analysis evaluating 763 patients found that patients who had a 
posterior pericardiotomy significantly reduced POAF (10.8% versus 28.1%, p=0.003; OR. 
0.33, 95% CI 0.16–0.69) and early (6.9% versus 46.2% p<.0001) or late (0% versus 11.3%, 
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p=0.0001) pleural effusion (Biancari & Mahar, 2010). The authors noted several limitations to 
the studies favoring pericardiotomy, including no data regarding hemodynamic instability, 
re-operation for bleeding and use of drugs for prevention of POAF (Biancari & Mahar, 
2010). Posterior pericardiotomy however is not risk free. Potential risks include cardiac 
herniation as well as compromise of grafts protruding thought the pericardiotomy (Biancari 
& Mahar, 2010).  
6.3 Coronary bypass surgery without the use of cardiopulmonary bypass  
(“Off-pump” CABG) 
The introduction of cardiac surgery without the use of cardiopulmonary bypass, also referred 
to as “off-pump”, has been hypothesized to lower the incidence of POAF. The multiple 
mechanisms hypothesized to cause POAF may all be avoided when coronary bypass surgery 
is completed without the use of the cardiopulmonary bypass circuit. Salamon et al evaluated a 
series of over 2500 patients with 252 undergoing “off-pump” coronary bypass surgery 
(Salamon et al., 2003). Patient on cardiopulmonary bypass had higher rates of atrial fibrillation 
and concluded that avoiding cardiopulmonary bypass did not aid in the reduction of AF. 
Another retrospective analysis by Enc and colleagues in 670 patients undergoing conventional 
compared to “off-pump” coronary bypass surgery, found a lower, but non-significant 
reduction in POAF respectively (16.1% versus 14.6%) (Enc et al., 2004).  
Elimination of the use of cardiopulmonary bypass in cardiac surgery has shown inconsistent 
results from meta-analyses and studies. Only the European EACTS 2006 guidelines supports 
its use as a non-pharmacologic option are the 2006 EACTS guidelines and include earlier meta-
analysis that show conflicting results (Dunning et al., 2006). Focus for the prevention of POAF 
in cardiac surgery patients should focus on the use more standard prophylactic regimens 
including beta-blockers, rather than explicit avoidance of cardiopulmonary bypass. 
6.4 Pericardial fat pad 
Two other novel non-pharmacologic options that have been studied include preservation of 
pericardial fat pad and regulation of body temperature during cardiac surgery which targets 
disruption of AV node and inflammation, respectively. The anterior fat pad is commonly 
disrupted to provide clear field of view while applying the cross clamp during cardiac 
surgery. The anterior fat pad is known to possess parasympathetic ganglia as well as vagal 
pathways (Singh et al., 1996). The fat pads located at the superior vena cava-atrial junction 
contain post ganglionic fibers that lead to the sino-atrial node (Carlson et al., 1992). The fat 
pads located at the pulmonary vein-left atrium contain post ganglionic fibers that innervate 
the atrio-ventricular node (Quan et al., 2001). These fat pads are analogous to dog 
physiology and has been determined that ablation of these fibers in dogs reduces 
susceptibility of POAF. In a study of 55 patients where the fat pad was preserved, a 
significant reduction of POAF was observed (Cummings et al., 2004). A significant 
limitation of this research includes a small sample size and not accounting for the use of 
beta-adrenergic blocking drugs. Secondarily the rate of atrial fibrillation in “off-pump” 
cardiac surgery remains a significant problem despite no manipulation of the epicardial fat 
pads (Salamon et al., 2003). 
6.5 Regulation of body temperature during surgery 
The other novel non-pharmacologic strategy is to regulate body temperature to limit 
systemic effects of the inflammatory cascade during cardiac surgery. Adams and colleagues 
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identified that hypothermia decreases sympathetic activation which lowers plasma 
norepinephrine levels and neuropeptide Y levels (Adams et al., 2000). A study randomized 
patients into two groups including mild hypothermia (34 C) and moderate hypothermia 
(28 C) and found no difference in the incidence of POAF between the groups, thus did not 
validate this pathophysiologic basis of POAF (Adams et al., 2000). The study was completed 
without benefit of knowledge regarding use of beta blockers or other adjunct measures to 
prevent POAF which could  influence the outcome of that study.. It should be noted that 
POAF is still common in beating heart surgery with normothermia, therefore negating the 
use of hypothermia as a valid tool in prevention of POAF. 
6.6 Maze procedure during open-heart surgery 
The surgical maze procedure, or Cox-maze procedure, uses surgical incisions in the atria to 
form scar tissue to interrupt possible macroreentrant circuits (Cox et al., 1991). Alternative 
energy sources including radiofrequency or cryothermia have been incorporated to create 
lesions blocking atrial conduction without surgical incision into the atria. These procedures 
can be effective in restoring sinus rhythm, however when it is combined with other open 
heart operations to treat chronic AF, operative morbidity is consistently increased (Banach, 
et al., 2010). It is usually only performed on patients needing open-heart surgery for other 
issues, such as valve replacement or repair or CABG. The Canadian and most recent 
European guidelines both mention surgical ablation, however it should only be considered 
in patients with symptomatic AF already undergoing cardiac surgery (Kerr & Roy, 2004; 
ESC, 2010). The Canadian guidelines additionally mention that it should be considered in 
patients with previous AF who are undergoing mitral valve surgery, who may be at higher 
risk of POAF (Kerr & Roy, 2004) 
7. Conclusion 
For the prevention of postoperative atrial fibrillation in patients undergoing cardiac surgery, 
pharmacologic prophylaxis with beta-blockers and amiodarone are widely utilized. 
Evidence based guidelines also support the use of sotalol, magnesium, and atrial pacing. 
While these agents reduce the incidence of POAF, they do not eliminate it. Thus, there is a 
need for additional effective therapies. Other strategies that may be beneficial for 
prophylaxis include dofetilide, renin-angiotensin-aldosterone-system modulators, statins, 
corticosteroids, omega-3 fatty acids, ascorbic acid, N-acetylcysteine, sodium nitroprusside, 
levosimendan or intraoperative maze procedure in symptomatic AF patients undergoing 
cardiac surgery. For most of these strategies, there is a need for additional large scale, 
adequately powered, clinical studies to determine the benefit before they can be considered 
for routine use. Identification of high risk patients undergoing cardiac surgery and use of 
appropriate pharmacologic and non-pharmacologic therapies may further reduce the 
incidence of POAF and lead to improvements in the overall morbidity and burden to the 
health care system.  
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